The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Open accessAbstract
BACKGROUND: Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer and may choose to undergo prophylactic bilateral total mastectomy. We investigated the efficacy of this procedure in such women. METHODS: We conducted a prospective study of 139 women with a pathogenic BRCA1 or BRCA2 mutation who were enrolled in a breast-cancer surveillance program at the Rotterdam Family Cancer Clinic. At the time of enrollment, none of the women had a history of breast cancer. Seventy-six of these women eventually underwent prophylactic mastectomy, and the other 63 remained under regular surveillance. The effect of mastectomy on the incidence of breast cancer was analyzed by the Cox proportional-hazards method in which mastectomy was modeled as a time-dependent covariate. RESULTS: No cases of breast cancer were observed after prophylactic mastectomy after a mean (+/-SE) follow-up of 2.9+/-1.4 years, whereas eight breast cancers developed in women under regular surveillance after a mean follow-up of 3.0+/-1.5 years (P=0.003; hazard ratio, 0; 95 percent confidence interval, 0 to 0.36). The actuarial mean five-year incidence of breast cancer among all women in the surveillance group was 17+/-7 percent. On the basis of an exponential model, the yearly incidence of breast cancer in this group was 2.5 percent. The observed number of breast cancers in the surveillance group was consistent with the expected number (ratio of observed to expected cases, 1.2; 95 percent confidence interval, 0.4 to 3.7; P=0.80). CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies on PM consistently show a risk reduction of breast cancer of at least 90% [1,2]”
From Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy (2009) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which has been shown to reduce the incidence of breast cancer by approximately 90% [57-59]”
From Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of BRCA1 or BRCA2 Pathogenic Variants (2026) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,428
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Lerman, C., Narod, S., Schulman, K., Hughes, C., Gomez-Caminero, A., Bonney, G., Gold, K., Trock, B., Main, D., Lynch, J., et al. (1996) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.275.24.1885 · Cited by 840
BRCA1 Testing in Families With Hereditary Breast-Ovarian Cancer
Lerman, C. E. (1996) · JAMA · doi:10.1001/jama.1996.03530480027036 · Cited by 826
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A. F., Snyder, C., Watson, P. A., Cannon‐Albright, L., Isaacs, C. J., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 670
Research works printed but not linked: 4
- Whittemore AS, 1997, Am J Hum Genet, 60, 496
- Hartmann LC, 2000, Proc Am Assoc Cancer Res, 41, 222
- Kriege M, 2000, Eur J Cancer, 36, S137
- Zion SM, 2000, Prog Proc Am Soc Clin Oncol, 19, 441a
Cited by
Sorted by citations
Items 701–800 of 970
Impact of Advances in Breast Cancer Management on Reconstructive and Aesthetic Breast Surgery
Dobke, M. K. (2012) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2012.07.015 · Cited by 2
Breast Cancer: Genetics and Risk Assessment
Tejada‐Berges, T. (2016) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000236 · Cited by 2
Family History: A Bridge Between Genomic Medicine and Disease Prevention
Scheuner, M. T., & Yoon, P. W. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369420-1.00042-1 · Cited by 2
Liebers, M. R. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788019958-00345 · Cited by 2
de Freitas, R. M., Medeiros, P. H. D. O., Guerra, M. R., & Bustamante-Teixeira, M. T. (2021) · Mastology · doi:10.29289/2594539420210041 · Cited by 2
Cellular and molecular mechanisms of breast cancer susceptibility
Shalabi, S., & LaBarge, M. A. (2022) · Clinical Science · doi:10.1042/cs20211158 · Cited by 2
Clarijs, M. E., van Egdom, L. S. E., Verhoef, C. K., Vasilic, D., & Koppert, L. B. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-066728 · Cited by 2
Breast cancer: from Halsted to Harney
Kell, M. (2014) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-014-1142-z · Cited by 2
“lactic mastectomy greater than 95 % lifetime risk reduction of breast cancer and prophylactic gynecological surgery not only dramatically reducing pelvic malignancy, but also a 75 % reduction in breast malignancy when performed in premenopausal women [14].”
BackgroundBREAST CANCER SCREENING; MAMMOGRAPHY VERSUS DYNAMIC MRI BREAST
Bukhari, D. H., Shaukat, A., & Ahmad, N. (2017) · The Professional Medical Journal · doi:10.17957/tpmj/17.3182 · Cited by 2
Is Smoking a Risk Factor of Breast Cancer?
Kwong, A. (2019) · Novel Approaches in Cancer Study · doi:10.31031/nacs.2019.02.000540 · Cited by 2
“It is well known that breast cancer susceptibility genes (BRCA1/2) are associated with increased risk of breast cancer [55].”
BackgroundDavid, M. A. B., Evron, E., Rasco, A. F., Shai, A., & Corn, B. W. (2021) · Cancers · doi:10.3390/cancers13112694 · Cited by 2
Scheufler, O. (2005) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000183380.56647.3c · Cited by 2
Molecular Genetic Analysis of Familial Breast Cancer in South Africa
Agenbag, G. (2005) · SUNScholar (Stellenbosch University) · Cited by 2
Ryan, P. D., Haber, D. A., Shannon, K. M., Smith, B. L., & Fan, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmcpc030018 · Cited by 2
Benns, M. V., Luk, T., & Scoggins, C. R. (2009) · The American Surgeon · doi:10.1177/000313480907500701 · Cited by 2
Molecular Diagnostics in Cancer
Kalachand, R. D., Hennessy, B. T., Bast, R. C., & Mills, G. B. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm041 · Cited by 2
Barbieri, R. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4907-4.00010-3 · Cited by 2
Popat, S., & Smith, I. E. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.04.003 · Cited by 2
RESPONSE: Re: Risk-Reduction Mastectomy: Clinical Issues and Research Needs
Stefanek, M. E., Hartmann, L. C., & Nelson, W. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.143-a · Cited by 2
Familiäres Mammakarzinom: Beratung, Gendiagnostik und Betreuung betroffener Familien
Schmutzler, R. K., & Meindl, A. (2006) · Springer eBooks · doi:10.1007/978-3-540-31748-7_14 · Cited by 2
Oluwole, S. F., & Oluwole, O. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-28127-3_30 · Cited by 1
Mashal, S., Melanson, A., Apostolova, C., Ferroum, A., Villareal-Corpuz, V., Meterissian, S. H., Martel, K., Boileau, J.-F., Basik, M., Foulkes, W. D., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19375-w · Cited by 1
Lloyd-Ellis, S., Kaur, P., Kwon, J. S., Dawson, L., & Hanley, G. E. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.05.018 · Cited by 1
Carlomagno, N., Pelosio, L., Jamshidi, A., Duraturo, F., Izzo, P., & Renda, A. (2009) · Springer eBooks · doi:10.1007/978-88-470-1095-6_17 · Cited by 1
Management of Women with Inherited BRCA1 and BRCA2 Mutations
Swisher, E. M., & Calhoun, K. E. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0477-5_2 · Cited by 1
Strategien zur Prävention des Mammakarzinoms
Bauerschlag, D., & Ruckhäberle, E. (2014) · Der Gynäkologe · doi:10.1007/s00129-013-3306-8 · Cited by 1
“Eine PBM kann das Erkrankungsrisiko an Brustkrebs um >90% sowohl bei familiärer als auch bei genetischer Prädisposition senken [9, 10].”
BackgroundBilateral Breast Reconstruction and the Role of Prophylactic Mastectomy
MacLennan, S. E. (2002) · Breast Disease · doi:10.3233/bd-2002-16105 · Cited by 1
Reduction Mammoplasty is Beneficial in Women with and Without History of Breast Cancer
Desouki, M. M. (2015) · Women s Health · doi:10.2217/whe.15.32 · Cited by 1
Breast Cancer Incidence and Risk Reduction with Special Reference to Muslim Countries
Haq, N., Haq, M. M., & Haque, A. K. (2009) · Journal of the Islamic Medical Association of North America · doi:10.5915/41-1-4424 · Cited by 1
Hereditary Breast Cancer in Korea
Kim, S. (2012) · Journal of genetic medicine · doi:10.5734/jgm.2012.9.1.1 · Cited by 1
Contralateral risk-reducing mastectomy in young women
Merck, B. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1037-2 · Cited by 1
“Existing data suggest that contralateral risk-reducing mastectomy may diminish by as much as 95% the risk of developing breast cancer in moderate- and high-risk women, particularly in women with ipsilateral breast cancer or known BRCA1/BRCA2 mutation [2, 5, 6].”
BackgroundMujeres con alta probabilidad de padecer cáncer de mama. Luces, sombras y muchos puntos oscuros
Caruncho, M. V. (2012) · Radiología · doi:10.1016/j.rx.2011.10.004 · Cited by 1
Smith, K. L., & Isaacs, C. J. (2011) · Current Breast Cancer Reports · doi:10.1007/s12609-011-0049-1 · Cited by 1
Frequency of the CHEK2 1100delC Mutation in Korean Women with Early Onset Breast Cancer
Choi, D. H., Cho, D. Y., Lee, M. H., Park, H. S., & Haffty, B. G. (2008) · Journal of Breast Cancer · doi:10.4048/jbc.2008.11.1.25 · Cited by 1
“(4, 5) 유전성유방암은젊은나이때부터정기검진을통해조기발견 하고, 매우민감한유전자검사를통해유전성을밝힐수있으며예 방적수술을통해유방암의발생빈도를줄이고생존율향상을기 대할수있다.(6) 그러나유전성유방암의경우조기발견을위한 정기검진도자주시행하여야하고MRI 등고가의장비를이용한”
Direct-to-Consumer Genetic Testing
Stein, R. A. (2012) · Journal of Information Technology Research · doi:10.4018/jitr.2012010103 · Cited by 1
Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers
Maxwell, K. N., & Domchek, S. M. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0086-4 · Cited by 1
Baildam, A. D. (2006) · The Breast · doi:10.1016/s0960-9776(07)70013-9 · Cited by 1
Increase in Mastectomies Performed in Patients in the Community Setting Undergoing MRI
Ayoola, A., Alagarsamy, S., Jaboin, J. J., & Rao, S. B. (2011) · The Breast Journal · doi:10.1111/j.1524-4741.2011.01063.x · Cited by 1
BRCA1 and BRCA2 Variants of Uncertain Significance. Part Two: Medical Management
Miller-Samuel, S., Rosenberg, A., Berger, A., Gomella, L. G., Loren, D. E., & Morris, G. J. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.04.009 · Cited by 1
Rhiem, K. E., & Pfeifer, K. (2014) · Der Gynäkologe · doi:10.1007/s00129-014-3347-7 · Cited by 1
Pharmacogenetics of Sulfonylureas
Kovacs, P. L., & Pearson, E. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_23 · Cited by 1
“Women with specific mutations in these genes are at high risk of developing breast cancer and thus are advised to undergo a prophylactic, bilateral mastectomy (Meijers-Heijboer et al. 2001).”
BackgroundRisk Management of Hereditary Breast Cancer
Arun, B. (2008) · CRC Press eBooks · doi:10.3109/9781420052886-8 · Cited by 1
Voltura, A., & Jacobs, L. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4932-6.50011-1 · Cited by 1
Yamauchi, H. (2016) · Springer eBooks · doi:10.1007/978-4-431-55552-0_3 · Cited by 1
“Data for risk reduction mastectomy (RRM) showed clearly risk reduction in more than 90 % for breast cancer [22–29].”
BackgroundHow Venom from the Magnificent Sea Anemone, Heteractis magnifica, Kills Breast and Lung Cancer Cells
Sanderson, B. J. S., da Silva, K. B., & Ramezanpour, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-31305-4_41 · Cited by 1
Ricci, C., Serra, M., Locatelli, F., Laudo, M. D., Zuntini, R., Santini, D., Taffurelli, M., & Turchetti, D. (2017) · Human Pathology Case Reports · doi:10.1016/j.ehpc.2016.10.008 · Cited by 1
Winchester, D. J., & Winchester, D. P. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00082-6 · Cited by 1
Hereditary Cancer Counseling and Germline Genetic Testing
Menendez, C. S., Marcom, P. K., & Sutton, L. (2021) · Springer eBooks · doi:10.1007/978-3-030-75377-1_20 · Cited by 1
Laustsen-Kiel, C. M., Lauritzen, E., Langhans, L., & Damsgaard, T. E. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052676 · Cited by 1
Pitiyarachchi, O., Phillips, K., & Friedlander, M. L. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100504 · Cited by 1
Management of Hereditary Breast Cancer: An Overview
Kattepur, A. K., & Gopinath, K. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-4546-4_18 · Cited by 1
Berg, W. A. (2007) · Springer eBooks · doi:10.1007/0-387-31056-8_28 · Cited by 1
Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer
Mansoor, S., Manzoor, U., Koul, A. M., Baba, S. M., Amin, I., Anwar, I., Aein, Q. U., & Pandith, A. A. (2022) · Springer eBooks · doi:10.1007/978-981-19-0197-3_5 · Cited by 1
Avances en la investigación genética del cáncer de mama: Mini Revisión
Salazar, F., Barreno-Sánchez, M. J., Bustillos, A., Hernandez, E. V., & Suero, L. E. L. (2023) · Investigación y Desarrollo · doi:10.31243/id.v18.2023.2064 · Cited by 8
Breast Cancer in the Ashkenazi Jewish Population
Frey, M. K., Perez, L. R., Brewer, J., Fleischmann, A., & Silber, E. (2024) · Current Breast Cancer Reports · doi:10.1007/s12609-024-00528-3 · Cited by 1
“Retrospective and prospective observational studies demonstrate that risk-reducing bilateral mastectomy decreases the incidence of breast cancer by at least 90% [19, 30–32].”
Risk-reducing surgery in BRCA carriers: do we need more evidence?
Sacchini, V. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00232-3 · Cited by 1
Dorval, M., Pelletier, S., Bouchard, K., Desbiens, C., & Chiquette, J. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1708 · Cited by 1
Familiäres Mammakarzinom — Beratung und Betreuung betroffener Familien
Schmutzler, R. K., & Kast, K. (2010) · Springer eBooks · doi:10.1007/978-3-642-12681-9_4 · Cited by 1
Genetische Risikofaktoren am Beispiel des familiären Mammakarzinoms
Rhiem, K., & Schmutzler, R. K. (2015) · Forum · doi:10.1007/s12312-014-1246-4 · Cited by 1
Genetics of Hereditary Breast Cancer
Ryan, P. D. (2010) · Springer eBooks · doi:10.1007/978-0-387-93846-2_3 · Cited by 1
Layer, G., Kauczor, H., Morris, E. A., Wintersperger, B. J., Johnson, T. R. C., Nikolaou, K., Huber, A. M. A., Bauner, K. U., Michaely, H. J., Schoenberg, S. O., et al. (2007) · Springer eBooks · doi:10.1007/978-3-540-29355-2_5 · Cited by 1
Hanf, V., & Emons, G. (2003) · Springer eBooks · doi:10.1007/978-3-662-07492-3_34 · Cited by 1
London, K. E. (2013) · Journal of Bioresource Management · Cited by 1
État de l’art des recommandations actuelles pour la chirurgie prophylactique
Pujol, P. (2012) · Springer eBooks · doi:10.1007/978-2-8178-0245-9_3 · Cited by 1
Physicians-in-Training Recommendations for Prophylactic Bilateral Mastectomies
Madan, A. K., Aliabadi‐Wahle, S., & Beech, D. J. (2003) · The Breast Journal · doi:10.1046/j.1524-4741.2003.09507.x · Cited by 1
“While the investigations may have been previously considered controversial (10), recent data in one study of women with BRCA1 / BRCA2 mutations support the use of PBM (9).”
ResultIdentifying and Managing the High-Risk Patient
Sabel, M. S. (2009) · Elsevier eBooks · doi:10.1016/b978-0-323-03758-7.00008-9 · Cited by 1
Operative ÜBerlegungen beim Familiôren Mammakarzinom
Bachleitner‐Hofmann, T., & Taucher, S. (2007) · Springer eBooks · doi:10.1007/978-3-211-29685-1_6 · Cited by 1
Present Options in the Prevention of Breast Cancer
Russo, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-72815-1_7 · Cited by 1
Lu, B. (2007) · Cited by 1
Colorectal Cancer at the Beginning of the New Millennium
de Leòn, M. P. (2002) · Springer eBooks · doi:10.1007/978-3-642-56008-8_14 · Cited by 1
Palmero, E. I. (2007) · Americanae (AECID Library) · Cited by 1
Strategies of Hormonal Prevention
Li, Y., & Brown, P. H. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-09463-2_10 · Cited by 1
“Previous reports indicated that mastectomy reduced the risk of breast cancer by 90–100% [35–37].”
BackgroundTollin, S. (2011) · Digital Commons - University of South Florida (University of South Florida) · Cited by 1
Escobar, K. A. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2011.tde-05092011-152557 · Cited by 1
Breast cancer susceptibility genes: Options for those carrying BRCA1 mutations
Brankovic-Magic, M. V., Janković, R., & Radulovic, S. S. (2002) · Archive of oncology · doi:10.2298/aoo0203119b · Cited by 1
Familial Breast Cancer – What are the Choices, What Are the Questions?
Schmutzler, R. K. (2006) · Breast Care · doi:10.1159/000090908 · Cited by 1
Risk Communication During Screening for Genomic Breast Cancer Susceptibility
Gramling, R. E., & Vidrine, J. I. (2007) · American Journal of Lifestyle Medicine · doi:10.1177/1559827606295453 · Cited by 1
Laparoscopic oophorectomy combined with breast surgery for breast cancer patients
Carmon, M., Olsha, O., Levy‐Lahad, E., Zuckerman, B., Rivkin, L., & Beller, U. (2006) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.14.19 · Cited by 1
Management of a woman with a family history of breast cancer
Lynch, E., & Eeles, R. A. (2006) · Women s Health Medicine · doi:10.1383/wohm.2006.3.1.28 · Cited by 1
de Castro, J. J. G., & Cruz, J. J. (2003) · Medicina Clínica · doi:10.1016/s0025-7753(03)73989-x · Cited by 1
Screening of Women with Hereditary Risk of Breast Cancer
Kuhl, C. K. (2004) · Clinical Breast Cancer · doi:10.1016/s1526-8209(11)70376-7 · Cited by 1
Integrative Tumor Board: Recurrent Breast Cancer or New Primary?
Hirsch, A. (2003) · Integrative Cancer Therapies · doi:10.1177/15347354030023011 · Cited by 1
“For patients known to have BRCA1 and BRCA2 mutations, prophylactic mastectomy has been shown to reduce the incidence of development of subsequent breast cancer.(35) The role of sentinel lymph node biopsy in the setting of prophylactic mastectomy similarly is unclear.”
BackgroundGenetic Testing for Breast and Ovarian Cancer
SILVERMAN, J. (2002) · Cited by 1
Fighting Breast Cancer: A Call for a New Paradigm
Binstock, M. A. (2005) · The Permanente Journal · doi:10.7812/tpp/04-108 · Cited by 1
Sentinel Lymph Node Surgery During Prophylactic Mastectomy (Methodology)
Boughey, J. C., & Bedrosian, I. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8369-3_37 · Cited by 1
BRCA Gene Mutations and Cancer
Zimmerman, V. L. (2002) · AJN American Journal of Nursing · doi:10.1097/00000446-200208000-00034 · Cited by 1
Eccleston, A., Bentley, A., Dyer, M., Strydom, A., Vereecken, W., George, A. J., & Rahman, N. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/060418 · Cited by 1
Reduction of Surgical Risk Through the Evaluation of Medical Imaging DiagnosticsPreprint
Grinet, M. A. V. M., García, N. M., Gouveia, A., Moutinho, J., & Gomes, A. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2003.08748 · Cited by 1
Delbrück, H. (2003) · Springer eBooks · doi:10.1007/978-3-642-55801-6_4 · Cited by 1
Microarrays: new pharmacogenomic tools for the Twenty-first Century
Sweeney, B. P. (2004) · European Journal of Anaesthesiology · doi:10.1017/s026502150400701x · Cited by 1
“Examples of this approach include screening for the BRCA1 and BRCA2 tumour suppressor genes in members of families with a history of breast cancer [7], screening for predisposition to some forms of heritable colonic cancer [8] and the detection of mutations in genes encoding cardiac ion channels, which can be the caus…”
BackgroundSchmutzler, R. K. (2008) · Wiley eBooks · doi:10.1002/9783527627523.ch11 · Cited by 1
Prédisposition génétique aux cancers du sein et de l’ovaire: Diagnostic moléculaire et conséquences
Delaloge, S., Albiges, L. K., Paillerets, B. B., & Chompret, A. (2006) · ONCOLOGIE · doi:10.1007/s10269-006-0361-y · Cited by 1
“– Mastectomieprophylactique : elle a fait l’objet de plus-ieurs publications majeures dans les dernières années et a suscité de nombreux débats (Tableau 2) [11,23,27].”
BackgroundGenetische Epidemiologie am Beispiel Brustkrebs
Chang-Claude, J. C., Fischer, C., & Schmutzler, R. K. (2006) · Der Onkologe · doi:10.1007/s00761-006-1139-y · Cited by 1
Abdel-Razeq, H., & Mansour, R. (2026) · World Journal of Oncology · doi:10.14740/wjon2692
Präventives Versorgungskonzept bei erblichem Brustkrebs
Rhiem, K., & Schmutzler, R. K. (2009) · Springer eBooks · doi:10.1007/978-3-540-73042-2_47
Präventive operative Optionen für Frauen mit einer familiären Brust- und Eierstockkrebsbelastung
Rhiem, K. (2015) · Medizinische Genetik · doi:10.1007/s11825-015-0046-2
“Während in der Gruppe der Frauen mit PBM (n = 76) innerhalb der mittleren Beobachtungszeit von 2,9 Jahren bei keiner Frau Brustkrebs diagnostiziert wurde, erkrankten hingegen 8 von 63 Frauen in der Früherkennungsgruppe (HR 0; 95 % CI 0–0,36; p = 0,003) [7].”
BackgroundBreast Cancer Families in Finland
Eerola, H. (2001) · Työväentutkimus Vuosikirja
Crohns, C., & Mundhenke, C. (2009) · Der Gynäkologe · doi:10.1007/s00129-009-2360-8
Rhiem, K., & Schmutzler, R. K. (2010) · Der Gynäkologe · doi:10.1007/s00129-009-2506-8
Genetische Beratung bei gynäkologischen Erkrankungen
Prieshof, B., & Costa, S. D. (2006) · Springer eBooks · doi:10.1007/3-540-31105-x_36
Metadata
- Authors
- Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., Brekelmans, C. T. M., & Klijn, J. G. M.
- Affiliations
- Erasmus MC (NL)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-07-19
- Volume
- 345
- Issue
- 3
- Pages
- 159-164
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2046809735
- Cited by
- 973
- References
- 33
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 14 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 23 · 2019: 30 · 2018: 21 · 2017: 37 · 2016: 42 · 2015: 28 · 2014: 34 · 2013: 29 · 2012: 42
- FWCI
- 35.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, bilateral prophylactic mastectomy, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, breast cancer incidence, breast cancer surveillance, genetic susceptibility to cancer
- MeSH terms
- Adult, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Neoplasm Proteins, Prospective Studies, Transcription Factors, Mastectomy, Simple, Proportional Hazards Models, Genes, BRCA1, BRCA2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
